GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » iNtRON Biotechnology Inc (XKRX:048530) » Definitions » EBIT

iNtRON Biotechnology (XKRX:048530) EBIT : ₩-5,674 Mil (TTM As of Sep. 2024)


View and export this data going back to 2011. Start your Free Trial

What is iNtRON Biotechnology EBIT?

iNtRON Biotechnology's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was ₩-1,317 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was ₩-5,674 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. iNtRON Biotechnology's annualized ROC % for the quarter that ended in Sep. 2024 was -17.73%. iNtRON Biotechnology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -24.94%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. iNtRON Biotechnology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -4.37%.


iNtRON Biotechnology EBIT Historical Data

The historical data trend for iNtRON Biotechnology's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iNtRON Biotechnology EBIT Chart

iNtRON Biotechnology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -957.42 18,235.24 12,211.16 11,824.66 -7,917.97

iNtRON Biotechnology Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3,138.08 -2,432.21 -771.92 -1,153.50 -1,316.82

Competitive Comparison of iNtRON Biotechnology's EBIT

For the Biotechnology subindustry, iNtRON Biotechnology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


iNtRON Biotechnology's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, iNtRON Biotechnology's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where iNtRON Biotechnology's EV-to-EBIT falls into.



iNtRON Biotechnology EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-5,674 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


iNtRON Biotechnology  (XKRX:048530) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

iNtRON Biotechnology's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=-6531.112 * ( 1 - 0.48% )/( (37448.038 + 35886.958)/ 2 )
=-6499.7626624/36667.498
=-17.73 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=94849.597 - 892.061 - ( 56509.498 - max(0, 1385.51 - 59616.162+56509.498))
=37448.038

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=90966.449 - 702.478 - ( 54377.013 - max(0, 1117.67 - 57051.641+54377.013))
=35886.958

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

iNtRON Biotechnology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-5267.284/( ( (20067.932 + max(1658.249, 0)) + (19047.853 + max(1462.437, 0)) )/ 2 )
=-5267.284/( ( 21726.181 + 20510.29 )/ 2 )
=-5267.284/21118.2355
=-24.94 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1355.051 + 1137.435 + 392.33199999999) - (892.061 + 0 + 334.508)
=1658.249

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(880.281 + 1183.731 + 347.62) - (702.478 + 0 + 246.717)
=1462.437

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

iNtRON Biotechnology's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2024 )
=-5674.439/129917.051
=-4.37 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


iNtRON Biotechnology EBIT Related Terms

Thank you for viewing the detailed overview of iNtRON Biotechnology's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


iNtRON Biotechnology Business Description

Traded in Other Exchanges
N/A
Address
137, Sagimakgol-ro, Jungwon-gu, Gyeonggi-do, Seongnam-si, KOR
iNtRON Biotechnology Inc is a Korea-based company principally engaged in the biotechnology industry. It develops, manufactures, and commercializes drugs for the treatment of infectious diseases. It is contributing to national health and national prevention through several (molecular) diagnostic products such as swine flu, VRE super bacteria, food poisoning, avian influenza and foot, and mouth disease. In addition, it is also engaged in the operation of a veterinary antibiotic alternative business and new biopharmaceuticals development business.

iNtRON Biotechnology Headlines

No Headlines